HUTCHMED (China) Limited

and thank you for standing by. Welcome to HodgeMed 2023 Full-Year Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you need to press star 11 on your telephone. You'll then hear an automated message advising your hand is raised. Please be advised that today's conference is being recorded. I'd now like to pass the call over to your first speaker today, Mr. Mark Lee, Senior Vice President, Corporate Management and Communications of Hachmed. Thank you. Please go ahead.

Thank you, Desmond. Welcome, everybody. Good morning, good afternoon, good evening. Just a brief message as usual. The performance results and operations of Hachmed are historic in nature, and past performance is no guarantee of the future. We've got forward-looking statements, which means Within the meaning of the safe harbor provisions of the US SEC, this presentation is for investors only, and information on pharmaceuticals are not intended as advertising or medical advice. This presentation contains statistical and other third-party data which we have not independently verified, so we can't guarantee on their accuracy. Nothing in this presentation constitutes an offer to the sale of shares. No representation warranty is implied on this information, and anything in this presentation should be read in conjunction with Archimedes' results for the year ended December 31st, 2023. So with that, I'd like to hand over to Dr. Weiguo Su, our CEO and Chief Scientific Officer. Weiguo.

Okay, thank you very much, Mark. Good evening, good morning. Welcome again to HUDGMAT 2023 annual results presentation. 2023 was an exceptional year for HUDGMAT. We focused on frequenting of global registration and launch with our partner Takeda while continuing to execute on our strategy towards profitability. This is a year where we made significant progress. The pipeline progressed significantly, now more significant than the US approval for Quintinib for advanced CRC, a historic milestone for HatchMed. Financially, we ended 2023 with a very strong cash position, thanks to the Takeda partnership and also strong growth from our China commercial operations. Next slide, slide number four. Let me quickly introduce the agenda today. So Johnny Chan, our CFO, will go through the financial results for the full year 2023, followed by commercial update. Mr. Chan Hong is not available today, and Johnny will cover for him. And next will be Dr. Wu, who will be giving a manufacturing update, particularly on our new facility and also our global supply strategy. Followed by Michael Hsieh, who will be giving an update on our late stage pipeline and a wrap up. I'll wrap it up and followed by Q&A. And for the Q&A, the full team will be available. Now, for details of all the updates, let me invite our CFO, Johnny, for financial results. Johnny.